Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation

Authors :: M. Romero Cristóbal
Marcus-Alexander Wörns
R. Prince
L. Scuddeler
G. Sapisochin
M.L. González-Diéguez
Claudio Zavaglia
Helene Regnault
Maria Margarita Anders
Federica Invernizzi
Jordi Bruix
Giuliana Amaddeo
Lucia Cesarini
M. Reig
Álvaro Díaz-González
Matteo Angelo Manini
Matthias Pinter
Marco Sanduzzi-Zamparelli
M. Fraile-López
R. Tortora
Tommy Ivanics
Stefano Mazza
P. Daechul Yoon
Maria Francesca Donato
M.J. Blanco Rodríguez
Vincenzo Mazzaferro
Federico Piñero
M. Varela
Carolin Czauderna
Gonzalo Crespo
A. Fernandez Yunquera
Gerda Elisabeth Villadsen
Massimo Iavarone
G. Aballay Soteras
M. De Giorgio
Pietro Lampertico
G.G. Di Costanzo
Sherrie Bhoori
Arndt Weinmann
Source :: Digestive and Liver Disease. 53:S11
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Sorafenib
Oncology
medicine.medical_specialty
Hepatology
business.industry
medicine.medical_treatment
Gastroenterology
Liver transplantation
chemistry.chemical_compound
chemistry
Regorafenib
Internal medicine
medicine
In patient
business
medicine.drug

Full Text Access

Tools